Dolutegravir/rilpivirine for the treatment of HIV-1 infection

Ellen Dowers,1 Francis Zamora,1 Lydia Aoun Barakat,2 Onyema Ogbuagu2 1Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 2Yale AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA Abstract: Much progress has been made in the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dowers E, Zamora F, Barakat LA, Ogbuagu O
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	dolutegravir rilpivirine antiretroviral therapy HIV Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/e2551025c57e4947ae941a02651ca03a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e2551025c57e4947ae941a02651ca03a
record_format	dspace
spelling	oai:doaj.org-article:e2551025c57e4947ae941a02651ca03a2021-12-02T07:05:54ZDolutegravir/rilpivirine for the treatment of HIV-1 infection1179-1373https://doaj.org/article/e2551025c57e4947ae941a02651ca03a2018-11-01T00:00:00Zhttps://www.dovepress.com/dolutegravirrilpivirine-for-the-treatment-of-hiv-1-infection-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373Ellen Dowers,1 Francis Zamora,1 Lydia Aoun Barakat,2 Onyema Ogbuagu2 1Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 2Yale AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA Abstract: Much progress has been made in the development of antiretroviral therapies (ARTs) for HIV-1 infection. Beginning a little over a decade ago, single tablet combination regimens (STRs) became available, and subsequently, newer STR formulations with improved safety profiles have emerged. Recently, there is a growing interest in regimen simplification with the primary goal of further reducing long-term toxicities of ART and improving medication adherence. Dolutegravir/rilpivirine (DTG/RPV) was approved by the US Food and Drug Administration (FDA) as the first dual antiretroviral STR for the maintenance therapy of HIV-1 infection. Following an extensive review of all published papers on RPV and DTG, administered alone and in combination, extracted from databases including PubMed, Google scholar, and EMBASE, as well as drug package inserts and conference abstracts and proceedings, this review discusses the chemical properties and composition, pharmacodynamics and pharmacokinetic properties, clinical trial efficacy and safety data, as well as important drug–drug interactions associated with DTG/RPV. An expert opinion section discusses ideal candidates for DTG/RPV in the context of available but limited data and in comparison to currently available and emerging ART alternatives. Keywords: dolutegravir, rilpivirine, antiretroviral therapy, HIVDowers EZamora FBarakat LAOgbuagu ODove Medical Pressarticledolutegravirrilpivirineantiretroviral therapyHIVImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol Volume 10, Pp 215-224 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	dolutegravir rilpivirine antiretroviral therapy HIV Immunologic diseases. Allergy RC581-607
spellingShingle	dolutegravir rilpivirine antiretroviral therapy HIV Immunologic diseases. Allergy RC581-607 Dowers E Zamora F Barakat LA Ogbuagu O Dolutegravir/rilpivirine for the treatment of HIV-1 infection
description	Ellen Dowers,1 Francis Zamora,1 Lydia Aoun Barakat,2 Onyema Ogbuagu2 1Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 2Yale AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA Abstract: Much progress has been made in the development of antiretroviral therapies (ARTs) for HIV-1 infection. Beginning a little over a decade ago, single tablet combination regimens (STRs) became available, and subsequently, newer STR formulations with improved safety profiles have emerged. Recently, there is a growing interest in regimen simplification with the primary goal of further reducing long-term toxicities of ART and improving medication adherence. Dolutegravir/rilpivirine (DTG/RPV) was approved by the US Food and Drug Administration (FDA) as the first dual antiretroviral STR for the maintenance therapy of HIV-1 infection. Following an extensive review of all published papers on RPV and DTG, administered alone and in combination, extracted from databases including PubMed, Google scholar, and EMBASE, as well as drug package inserts and conference abstracts and proceedings, this review discusses the chemical properties and composition, pharmacodynamics and pharmacokinetic properties, clinical trial efficacy and safety data, as well as important drug–drug interactions associated with DTG/RPV. An expert opinion section discusses ideal candidates for DTG/RPV in the context of available but limited data and in comparison to currently available and emerging ART alternatives. Keywords: dolutegravir, rilpivirine, antiretroviral therapy, HIV
format	article
author	Dowers E Zamora F Barakat LA Ogbuagu O
author_facet	Dowers E Zamora F Barakat LA Ogbuagu O
author_sort	Dowers E
title	Dolutegravir/rilpivirine for the treatment of HIV-1 infection
title_short	Dolutegravir/rilpivirine for the treatment of HIV-1 infection
title_full	Dolutegravir/rilpivirine for the treatment of HIV-1 infection
title_fullStr	Dolutegravir/rilpivirine for the treatment of HIV-1 infection
title_full_unstemmed	Dolutegravir/rilpivirine for the treatment of HIV-1 infection
title_sort	dolutegravir/rilpivirine for the treatment of hiv-1 infection
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/e2551025c57e4947ae941a02651ca03a
work_keys_str_mv	AT dowerse dolutegravirrilpivirineforthetreatmentofhiv1infection AT zamoraf dolutegravirrilpivirineforthetreatmentofhiv1infection AT barakatla dolutegravirrilpivirineforthetreatmentofhiv1infection AT ogbuaguo dolutegravirrilpivirineforthetreatmentofhiv1infection
_version_	1718399607508041728

Dolutegravir/rilpivirine for the treatment of HIV-1 infection

Ejemplares similares